Vitrafy Life Sciences (VFY) Q3 2025 TU earnings summary

Operational and Commercial Highlights

• Completed Phase 1 blood platelet study with the US Army Institute of Surgical Research, achieving over 88% post-thaw recovery and exceeding regulatory standards for human health applications.

• Awarded AUD 4.8 million Industry Growth Program grant from the Australian government to accelerate VCU2 development and commercialisation.

• Expanded US operations with the appointment of a VP of Business Development and ongoing business development activities in all target sectors.

• Continued strong progress in animal health, with a 55.3% CAGR in salmon milt cryopreservation, increased pack processing, and expansion in aquaculture and bovine semen trials.

• Ongoing development of VCU2 and LifeChain software, with launches expected in H2 2025 and H1 FY2026, respectively.

Financial Position and Outlook

• Maintained robust liquidity at approximately AUD 34 million, with A$13.97m in cash and A$20.1m in term deposits at quarter end.

• Average monthly cash outflow was about A$1.1m, with a net cash movement of A$(0.5)m for the quarter.

• Q4 will see increased expenditure due to higher headcount and product development, focused on commercialisation and business development.

• Expenditure for the quarter was $3.05m, including $341,000 paid to directors and related parties.

• Estimated quarters of funding available is 39.4 based on cash and cash equivalents, or 95.8 including term deposits.

Strategic and Market Developments

• Engaged in commercial discussions with the US Army and planning Phase 2 validation for higher throughput.

• Building relationships with US biobanks and Blood Centers of America for blood market entry.

• No-cryoprotectant technology is a key differentiator, eliminating toxic washout steps and simplifying processes.

• Collaboration with Select Sires, Inc. advancing, with Phase 2 onsite trial in Ohio planned and results expected in Q4.

• Manufacturing strategy includes US-based assembly to mitigate tariff risks.